NYSE:RMD ResMed - RMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $224.60 -2.01 (-0.89%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$223.28▼$227.2550-Day Range$205.07▼$236.5352-Week Range$189.40▼$262.38Volume536,423 shsAverage Volume710,047 shsMarket Capitalization$33.00 billionP/E Ratio40.76Dividend Yield0.77%Price Target$263.17 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ResMed MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside17.3% Upside$263.17 Price TargetShort InterestHealthy0.59% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-1.03Upright™ Environmental ScoreNews Sentiment0.21Based on 26 Articles This WeekInsider TradingSelling Shares$10.43 M Sold Last QuarterProj. Earnings Growth12.64%From $6.41 to $7.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.75 out of 5 starsMedical Sector52nd out of 1,029 stocksSurgical & Medical Instruments Industry5th out of 107 stocks 2.4 Analyst's Opinion Consensus RatingResMed has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $263.17, ResMed has a forecasted upside of 17.3% from its current price of $224.27.Amount of Analyst CoverageResMed has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.59% of the float of ResMed has been sold short.Short Interest Ratio / Days to CoverResMed has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ResMed has recently decreased by 15.84%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldResMed has a dividend yield of 0.77%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthResMed has only been increasing its dividend for 2 years.Dividend CoverageThe dividend payout ratio of ResMed is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, ResMed will have a dividend payout ratio of 24.38% next year. This indicates that ResMed will be able to sustain or increase its dividend. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreResMed has received a 51.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Personal health record software" and "Medical ventilators" products. See details.Environmental SustainabilityThe Environmental Impact score for ResMed is -1.03. Previous Next 2.3 News and Social Media Coverage News SentimentResMed has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for ResMed this week, compared to 5 articles on an average week.Search Interest7 people have searched for RMD on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,430,328.00 in company stock.Percentage Held by InsidersOnly 1.39% of the stock of ResMed is held by insiders.Percentage Held by Institutions64.73% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for ResMed are expected to grow by 12.64% in the coming year, from $6.41 to $7.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ResMed is 40.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.22.Price to Earnings Ratio vs. SectorThe P/E ratio of ResMed is 40.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.92.Price to Earnings Growth RatioResMed has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioResMed has a P/B Ratio of 8.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ResMed (NYSE:RMD) StockResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.Read More Receive RMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter. Email Address RMD Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comResMed (NYSE:RMD) Rating Reiterated by William BlairFebruary 1, 2023 | americanbankingnews.comQ3 2023 Earnings Estimate for ResMed Inc. (NYSE:RMD) Issued By KeyCorpFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 31, 2023 | americanbankingnews.comBrokers Issue Forecasts for ResMed Inc.'s Q3 2023 Earnings (NYSE:RMD)January 30, 2023 | americanbankingnews.comResMed (NYSE:RMD) PT Raised to $260.00January 28, 2023 | finance.yahoo.comResMed Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS In LineJanuary 26, 2023 | finance.yahoo.comResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair EmeritusJanuary 26, 2023 | finance.yahoo.comResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023February 3, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 16, 2023 | finance.yahoo.comResMed's (NYSE:RMD) 21% CAGR outpaced the company's earnings growth over the same five-year periodJanuary 12, 2023 | finance.yahoo.comResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023December 8, 2022 | finance.yahoo.comResMed Inc.'s (NYSE:RMD) recent 3.5% pullback adds to one-year year losses, institutional owners may take drastic measuresNovember 22, 2022 | finance.yahoo.comResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software SolutionsNovember 10, 2022 | finance.yahoo.comHere's Why Shareholders Will Not Be Complaining About ResMed Inc.'s (NYSE:RMD) CEO Pay PacketOctober 27, 2022 | finance.yahoo.comResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023October 17, 2022 | fool.com.au2 classic healthcare ASX shares priced to buy now: expert - The Motley Fool AustraliaOctober 17, 2022 | globenewswire.comCPAP Devices Market Size is projected to reach USD 5254.51 million by 2030, growing at a CAGR of 7.4%: Straits Research - GlobeNewswireOctober 14, 2022 | fool.com.auWhat's the outlook for ASX healthcare shares in Q2? - The Motley Fool AustraliaOctober 14, 2022 | benzinga.comResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022 - ResMed (NYSE:RMD) - BenzingaOctober 13, 2022 | finance.yahoo.comResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022October 12, 2022 | globenewswire.comSleep Apnea Devices Market Size to Surpass US$ 12.86 Billion by 2030 - Growth Plus Reports - GlobeNewswireOctober 7, 2022 | nytimes.comHow a Hasidic Wedding in the UAE Went Viral on Instagram - The New York TimesSeptember 26, 2022 | finance.yahoo.comResMed (RMD) Gains on Product Uptake Even as Expenses RiseSeptember 25, 2022 | fool.com.auNot all ASX 200 shares are getting hammered today. Here are some winners - The Motley Fool AustraliaSeptember 25, 2022 | fool.com.auExperts names the blue chip ASX 200 shares to buy - The Motley Fool AustraliaSeptember 22, 2022 | benzinga.comHopeful Golden Cross Forms On ResMed's Chart - ResMed (NYSE:RMD) - BenzingaSeptember 21, 2022 | fool.com.auExperts name 2 outstanding ASX 200 shares to buy right now - The Motley Fool AustraliaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter. Email Address RMD Company Calendar Ex-Dividend for 12/15 Dividend11/09/2022Dividend Payable12/15/2022Last Earnings1/26/2023Today2/03/2023Ex-Dividend for 3/16 Dividend2/08/2023Dividend Payable3/16/2023Next Earnings (Estimated)4/27/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:RMD CUSIP76115210 CIK943819 Webwww.resmed.com Phone(858) 836-5000Fax858-836-5501Employees8,160Year Founded1989Price Target and Rating Average Stock Price Forecast$263.17 High Stock Price Forecast$280.00 Low Stock Price Forecast$245.00 Forecasted Upside/Downside+17.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$5.51 Trailing P/E Ratio40.76 Forward P/E Ratio35.04 P/E Growth2.15Net Income$779.44 million Net Margins21.51% Pretax Margin26.57% Return on Equity25.46% Return on Assets16.09% Debt Debt-to-Equity Ratio0.48 Current Ratio3.17 Quick Ratio1.82 Sales & Book Value Annual Sales$3.58 billion Price / Sales9.22 Cash Flow$7.00 per share Price / Cash Flow32.07 Book Value$25.44 per share Price / Book8.83Miscellaneous Outstanding Shares146,910,000Free Float144,867,000Market Cap$33.00 billion OptionableOptionable Beta0.47 Social Links Key ExecutivesMick FarrellChairman & Chief Executive OfficerRob DouglasPresident & Chief Operating OfficerBrett A. SandercockChief Financial OfficerCarlos M. NunezChief Medical OfficerUrvashi TyagiChief Technology OfficerKey CompetitorsDexComNASDAQ:DXCMBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDAbiomedNASDAQ:ABMDTeleflexNYSE:TFXView All CompetitorsInsiders & InstitutionsFisher Asset Management LLCSold 2,494 shares on 2/3/2023Ownership: 0.045%Illinois Municipal Retirement FundBought 1,074 shares on 2/3/2023Ownership: 0.036%Securian Asset Management Inc.Sold 126 shares on 2/3/2023Ownership: 0.008%Ellevest Inc.Sold 273 shares on 2/3/2023Ownership: 0.000%Dearborn Partners LLCSold 57 shares on 2/2/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions RMD Stock - Frequently Asked Questions Should I buy or sell ResMed stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RMD shares. View RMD analyst ratings or view top-rated stocks. What is ResMed's stock price forecast for 2023? 8 analysts have issued 1 year price objectives for ResMed's stock. Their RMD share price forecasts range from $245.00 to $280.00. On average, they predict the company's stock price to reach $263.17 in the next year. This suggests a possible upside of 17.0% from the stock's current price. View analysts price targets for RMD or view top-rated stocks among Wall Street analysts. How have RMD shares performed in 2023? ResMed's stock was trading at $208.13 at the beginning of the year. Since then, RMD stock has increased by 8.1% and is now trading at $224.92. View the best growth stocks for 2023 here. Are investors shorting ResMed? ResMed saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 850,000 shares, a decrease of 15.8% from the December 31st total of 1,010,000 shares. Based on an average daily trading volume, of 584,000 shares, the short-interest ratio is currently 1.5 days. Approximately 0.6% of the shares of the company are short sold. View ResMed's Short Interest. When is ResMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our RMD earnings forecast. How were ResMed's earnings last quarter? ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, January, 26th. The medical equipment provider reported $1.66 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.04. The medical equipment provider earned $1.03 billion during the quarter, compared to the consensus estimate of $996.22 million. ResMed had a trailing twelve-month return on equity of 25.46% and a net margin of 21.51%. The business's revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter last year, the company earned $1.47 earnings per share. Read the conference call transcript. How often does ResMed pay dividends? What is the dividend yield for ResMed? ResMed announced a quarterly dividend on Thursday, January 26th. Stockholders of record on Thursday, February 9th will be paid a dividend of $0.44 per share on Thursday, March 16th. This represents a $1.76 annualized dividend and a yield of 0.78%. The ex-dividend date is Wednesday, February 8th. Read our dividend analysis for RMD. Is ResMed a good dividend stock? ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.77%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.38% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RMD. What is Mick Farrell's approval rating as ResMed's CEO? 284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ResMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM). What is ResMed's stock symbol? ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD." Who are ResMed's major shareholders? ResMed's stock is owned by a number of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Welch & Forbes LLC (0.21%), Ardevora Asset Management LLP (0.15%), New York State Common Retirement Fund (0.12%) and New York State Teachers Retirement System (0.11%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor. View institutional ownership trends. How do I buy shares of ResMed? Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ResMed's stock price today? One share of RMD stock can currently be purchased for approximately $224.92. How much money does ResMed make? ResMed (NYSE:RMD) has a market capitalization of $33.04 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.51 on an earnings per share basis. How many employees does ResMed have? The company employs 8,160 workers across the globe. Does ResMed have any subsidiaries? The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.Read More How can I contact ResMed? ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501. This page (NYSE:RMD) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.